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Introduction
About 2500 to 3000 new pediatric malignancies are diag-
nosed every year in Japan. Recent progress using a 
combination of surgery, chemotherapy, and radiotherapy 
has improved survival and almost 70% of patients can 
now be cured [1]. However, late toxicities of radiotherapy 
are a problem in long- term survivors because children 
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Abstract
Recent progress in the treatment for pediatric malignancies using a combination 
of surgery, chemotherapy, and radiotherapy has improved survival. However, 
late toxicities of radiotherapy are a concern in long- term survivors. A recent 
study suggested reduced secondary cancer and other late toxicities after proton 
beam therapy (PBT) due to dosimetric advantages. In this study, we evaluated 
the safety and efficacy of PBT for pediatric patients treated in Japan. A retro-
spective observational study in pediatric patients who received PBT was per-
formed. All patients aged <20 years old who underwent PBT from January 
1983 to August 2014 at four sites in Japan were enrolled in the study. There 
were 343 patients in the study. The median follow- up periods were 22.6 months 
(0.4–374.3 months) for all patients and 30.6 months (0.6–374.3 months) for 
survivors. The estimated 1- , 3- , 5- , and 10- year survival rates were 82.7% (95% 
CI: 78.5–87.0%), 67.4% (61.7–73.2%), 61.4% (54.8–67.9%), and 58.7% (51.5–
65.9%), respectively. Fifty- two events of toxicity ≥ grade 2 occurred in 43  patients. 
Grade 4 toxicities of myelitis, visual loss (two cases), cerebral vascular disease, 
and tissue necrosis occurred in five patients. This study provides preliminary 
results for PBT in pediatric patients in Japan. More experience and follow- up 
with this technique are required to establish the efficacy of PBT in this patient 
population.
Cancer Medicine
Open Access
1520 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
M. Mizumoto et al.PBT for Pediatric Malignancy
have higher radiation sensitivity and lower radiation toler-
ance than adults. Reduction in quality of life due to growth 
and development retardation and secondary cancer is also 
a significant problem for pediatric patients [2, 3].
The energy of X- rays commonly used for the treatment 
of pediatric malignancies reaches a peak at a certain depth 
and then gradually declines along the irradiation pathway. 
Therefore, some normal tissue close to the target tumor 
receives a high dose. Intensity- modulated radiotherapy 
(IMRT) has made it possible to irradiate a complex tumor 
that is difficult to treat with traditional photon radio-
therapy, and progress with four- dimensional radiotherapy 
now permits precise diagnostic imaging. However, the 
lower dose area is increased with these techniques and 
this leads to a significant risk of secondary cancer [4].
In contrast, proton beams have a sharp Bragg peak, 
with low energy before the peak and almost zero energy 
after the peak. Therefore, in proton beam therapy (PBT), 
normal tissue around the tumor receives a reduced dose 
compared to photon radiotherapy, and this is especially 
beneficial for pediatric tumors or tumors adjacent to 
normal tissue for which irradiation should be strictly 
avoided [5]. Recent studies show that PBT can reduce 
the rate of secondary cancer in long- term follow- up [6–8]. 
In PBT, the tumor control rate is similar to that in photon 
radiotherapy [9–20], but late toxicity and the secondary 
cancer risk should be much lower due to the dose dis-
tribution [21]. For this reason, PBT has potential as a 
treatment for pediatric tumors, but fewer institutions have 
proton beam centers compared to those with normal 
photon radiotherapy. In this study, we evaluated PBT for 
pediatric patients in a multicenter study.
Patients and Methods
A retrospective observational study in pediatric patients 
who received PBT was performed at four institutions in 
Japan. All patients aged <20 years old who received PBT 
at these sites from January 1983 to August 2014 were 
enrolled without exclusion. The endpoints of the study 
were safety and efficacy. Data were collected for date of 
birth, sex, height, weight, disease, reason for PBT, potential 
for other treatment (photon radiotherapy, surgery), clinical 
target volume, tumor size, irradiation port number, dose 
fractionation and treatment period, reference point, com-
bination treatment, sedation, performance status (PS) at 
the start of treatment, dose to organ at risk, start and end 
day of PBT, early toxicity, late toxicity, last survival date 
or date of death, secondary cancer, discontinuation of PBT, 
and possible comparison of dose distribution to IMRT.
Individual information for each patient was SSL 
encrypted and anonymized. For patients who were 
followed at an institution other than that at which PBT 
Table 1. Patients and proton beam therapy characteristics.
Age (median) 0–19 (7)
Sex (male/female) 190/153
Disease
 Brain tumor 79
 Rhabdomyosarcoma 71
 Neuroblastoma 46
 Ewing sarcoma 30
 Head and neck carcinoma 27
 Chordoma 14
 Brain stem tumor 17
 AVM 8
 Others 51
Irradiation site
 Central nervous system 126
 Head and neck 105
 Abdomen 35
 Chest 45
 Pelvis 24
 Extremities 2
 Others 6
PS (0/1/≥2) 209/103/29 (unknown 2)
Initial treatment or recurrence 257/86
Multiple primary cancer
 No/Yes 336/7
Recent irradiation
 No/Yes 301/421
Surgery
 None/preirradiation/postirradiation 120/216/7
Chemotherapy
 None/pre/pre + concurrent/concurrent 72/124/116/31
Total dose (median) 10.8–100 GyE (50.4 GyE)
Combination with photon radiotherapy
 Yes/No 24/319
Target volume
 <100 cc 146
 100–500 cc 150
 >500 cc 43
AVM, cerebral arteriovenous malformation.
1Fields overlap: 32.
Table 2. Availability of photon radiotherapy and purpose of proton 
beam therapy (PBT).
Availability of photon radiotherapy
 Available, but with increasing risk 285
 Unavailable due to critical risk 41
 Available with equal risk to PBT 14
 Unknown 3
Reason of PBT (multiple selection)
 Reduction of growth retardation 310
 Reduction of secondary cancer 298
 Overdoses of normal tissues by photon radiotherapy 99
 Previous irradiation 25
 Patients’ wish 14
 Other 3
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was administered, entry into the study was determined 
based on the rules of the follow- up hospital or with ethi-
cal approval. Survival was analyzed using the Kaplan–Meier 
method (SPSS, IBM Inc. NY, USA).
Results
The characteristics of the 343 patients in the study are 
shown in Table 1. There were 190 males and 153 females, 
and the median age of all patients was 7 years old (range: 
0–19). PS were 0, 1, 2, and unknown for 209, 103, 29, 
and 2 patients, respectively. PBT was used as a component 
of initial therapy in 257 patients and for recurrence in 86 
patients. Seven patients had multiple primary cancer. Forty- 
two patients had received other radiotherapy before PBT 
and the irradiation field in PBT overlapped with the previ-
ous field in 32 of these patients. Surgery was conducted 
before PBT in 216 patients and after PBT in 7 patients, 
and 147 patients received concurrent chemotherapy.
The irradiation dose ranged from 10.8 to 100 GyE 
(median: 50.4 GyE) and 24 patients received PBT and 
photon radiotherapy in combination. The irradiation vol-
umes were <100 cc, 100–500 cc, >500 cc, and unknown 
in 146, 150, 43, and 4 patients, respectively, and 1, 2, 3, 
and ≥4 ports were used in 51, 147, 57, and 88 patients, Figure 1. Overall survival curve for all patients.
Overall survival (n = 343) 
1 year   82.7% (95%CI; 78.5-87.0) 
3 year   67.4% (61.7-73.2) 
5 year   61.4% (54.8-67.9) 
10 year  58.7% (51.5-65.9)   
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Figure 2. Comparison of overall survival between (A) new and recurrent cases, (B) patients with and without a history of irradiation, (C) patients for 
whom photon radiotherapy was possible and not possible, and (D) patients with a potential overdose and a tolerable dose in photon radiotherapy. 
Overall survival was compared, nonirradiation versus previous irradiation (2B), and photon radiotherapy could be used versus photon radiotherapy 
could not be used (2C).
New case (n = 257)
1 year   86.8% (95%CI:82.4-91.2)
3 year   73.7% (67.4-80.0)
5 year   69.7% (62.8-76.5)
Recurrent case (n = 86)
1 year 70.7% (60.6-80.8)
3 year 50.1% (38.1-62.0)
5 year 35.9% (20.5-51.4)
P = 0.0011.0
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P = 0.0001
Photon RT could be used (n = 285) 
1 year    86%
3 year    73%
5 year    71%
10 year  69%
Photon RT could not be used (n = 41)
1 year     71%
3 year     50%
5 year     31%
10 year   26%
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P = 0.001
Within tolerant dose by photon RT (n = 244)
1 year   83 %
3 year   69 %
5 year   67 %
10 year 67 %
Overdose by photon RT (n = 99)
1 year 82 %
3 year 63 %
5 year 51 %
10 year 44%
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respectively. The availability of photon radiotherapy and 
reasons for performing PBT are shown in Table 2. The 
information in Table 2 is based on the judgment of radia-
tion oncologists at each facility.
Photon radiotherapy could not be used in 41 patients 
because of critical toxicities, and 99 patients received PBT 
because an adjacent organ could not tolerate photon 
radiotherapy. The type of treated tumor and the irradia-
tion site are shown in Table 1. Of 41 patients for whom 
it was considered difficult to perform photon radiotherapy, 
3 had late toxicity ≥ grade 2 and 24 died of tumor pro-
gression (n = 22), secondary malignancy (n = 1), and 
accidental death (n = 1).
The median follow- up periods were 22.6 months (0.4–
374.3 months) for all patients and 30.6 months (0.6–
374.3 months) for survivors. The estimated 1- , 3- , 5- , and 
10- year survival rates were 82.7% (95% CI: 78.5–87.0%), 
67.4% (61.7–73.2%), 61.4% (54.8–67.9%), and 58.7% 
(51.5–65.9%), respectively (Fig. 1). Overall survival was 
significantly poorer for recurrent disease (P = 0.001; 
Fig. 2A) and significantly better for patients who had not 
received previous irradiation (P = 0.001; Fig. 2B). Survival 
was also better for patients who could have received photon 
radiotherapy instead of PBT compared to those who could 
not receive photon radiotherapy due to anticipated critical 
toxicities (P = 0.001; Fig. 2C). However, performance of 
PBT, because the normal tissue dose exceeded a threshold 
in photon radiotherapy, was not a significant factor influ-
encing survival (P = 0.06; Fig. 2D). The estimated 1- , 3- , 
and 5- year survival rates of brain tumor/rhabdomyosar-
coma/neuroblastoma/Ewing sarcoma were 91.4%, 81.7%, 
and 81.7%/84.5%, 74.3%, and 66.5%/72.0%, 57.6%, and 
57.6%/88.6%, 73.1%, and 56.8%, respectively (Figs. 3, 4).
Toxicity events except for secondary cancer are shown in 
Table 3. There were 52 events of toxicity ≥ grade 2 in 43 
patients. Grade 4 toxicities of myelitis, visual loss (2 cases), 
cerebral vascular disease, and tissue necrosis occurred in five 
patients, including 3 (60%) who were considered to be unable 
to tolerate photon radiotherapy (Tables 3 and 4). A 
Figure 4. Number of patients treated by proton beam therapy per year.
Table 3. Toxicity for all patients.
Grade 2 3 4
Bone deformity 8 2 0
Growth hormone deficiency 7 1 0
Thyroid dysfunction 7 0 0
Visual/hearing impairment 3 1 2
Brain necrosis/CVD 2 2 1
Gastric/duodenum ulcer 0 1 0
Pneumonitis 0 1 0
Dysphagia 0 1 0
Myelitis 0 0 1
Tissue necrosis 0 0 1
CVD, cerebral vascular disease.
Figure 3. Overall survival curve for brain tumor, rhabdomyosarcoma, 
neuroblastoma, Ewing sarcoma.
Brain tumor (n = 79)
1 year   91.4%
3 year    81.7% 
5 year    81.7%
Rhabdomyosarcoma (n = 71)
1 year 84.5% 
3 year 74.3%
5 year 66.5% 
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Neuroblastoma (n = 46)
1 year   72.0%
3 year   57.6% 
5 year   57.6%
Ewing sarcoma (n = 30)
1 year   88.6%
3 year   73.1% 
5 year   56.8%
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secondary tumor developed in seven patients, including two 
patients with solid malignancies (osteosarcoma and thyroid 
cancer), four with blood malignancies, and one with benign 
pituitary adenoma. In- field tumor development only occurred 
in the patient with pituitary adenoma (Table 5).
Discussion
Reduced toxicity is expected following PBT in pediatric 
patients because of the favorable dose distribution. In 
particular, the secondary cancer risk is likely to be much 
reduced in PBT compared to IMRT because IMRT requires 
many ports to reach a satisfactory dose distribution and 
this increases the low dose area. Comparisons of the 
dose distributions of IMRT and PBT have shown clear 
advantages of PBT. Hilbrant et al. suggested that the 
risk of secondary cancer in PBT was half that in IMRT 
for neuroblastoma and Wilms tumor, and Zhang et al. 
found that PBT reduces the risk of secondary cancer 
and cardiac mortality in craniospinal irradiation for 
medulloblastoma. The lifetime attributed risk for proton/
photon therapy ranges from 0.1 to 0.22 and 0.12 to 
0.24 for secondary cancer and cardiac mortality, respec-
tively [22]. Sethi et al. showed that PBT can reduce the 
risk of secondary malignancy based on significantly dif-
ferent 10- year cumulative incidences of RT- induced or 
in- field secondary malignancies of 0% for PBT and 14% 
for photon radiotherapy in respective follow- up periods 
of 6.9 and 13.1 years [22]. It should be noted that these 
periods are still relatively short for this kind of assess-
ment. In our study, 6 (1.7%) of 343 patients had a 
secondary malignancy, but our follow- up period is clearly 
too short for complete evaluation of the risk of second-
ary malignancy.
In this study, patients who received PBT in 1983 were 
included, but the median follow- up periods were only 
22.6 months (range: 0.4–374.3 months) for all patients and 
30.6 months (range: 0.6–374.3 months) for survivors. This 
Table 4. Grades 3 and 4 toxicities.
Grade Disease Toxicity
Age/
Sex
Dose fractionation 
irradiation volume (cc) Previous irradiation
Availability 
of PRT
Overdoses in 
case photon RT?
3 Abdominal Ewing Gastric ulcer 14/F 55.8GyE/31fr >500 No Available No
3 RMS Bone deformity 12/M 39.6GyE/22fr <100 Yes (overlapping +) Available No
3 Head and neck 
cancer
Dysphagia and 
pneumonitis
16/M 76GyE/38fr 100–500 No Available Yes
3 Maxilla osteosarcoma Oss deformity 10/F 59.4GyE/33fr <100 No Available No
3 Brain tumor Cerebral 
infarction
3/M 50.4GyE/28fr 100–500 No Available No
3 AVM Brain necrosis 13/F 24GyE/1fr <100 No Available No
3 Head and neck 
cancer
Hearing loss 18/F 72GyE/36fr <100 No Available Yes
3 Head and neck 
cancer
Hearing 
impairment
2/M 50.4GyE/28fr 100–500 No Available Yes
4 Ewing Myelitis 4/F 55.8GyE/31fr 100–500 No Available No
4 Chordoma Dysopia 18/M 70GyE/25fr <100 Yes (overlapping +) Available Yes
4 Head and neck 
cancer
CVD 16/M 76GyE/38fr 100–500 No Available Yes
4 Pelvic osteosarcoma Tissue necrosis 15/F 70.4GyE/16fr >500 No Unavailable Yes
4 Ewing Dysopia 15/M 59.4GyE/33fr 100–500 No Available No
Table 5. Secondary tumor.
Disease
Age/
Sex
Total dose/irradiation 
volume Secondary tumor
Outside/inside the 
irradiation field
Prognosis time 
from PBT (year)
Head and neck RMS 15/M 60 GyE/100–500 cc Osteosarcoma Outside 13.2
Maxillary sinus carcinoma 4/F 40 GyE/<100 cc Thyroid cancer (papillary carcinoma) Outside 8.1
Ewing sarcoma 15/F 55.8 GyE/100–500 cc MDS – 3.1
Abdominal RMS 1/F 54 GyE/100–500 cc MDS – 3
Medulloblastoma 4/M 55.8 GyE/>500 cc AML – 1.9
Pelvic RMS 5/M 50.4 GyE/>500 cc AML – 1.8
Chordoma 14/F 65 GyE/<100 cc Pituitary adenoma Inside 8.8
RMS, rhabdomyosarcoma; MDS, myelodysplastic syndrome; AML, acute myelogenous leukemia; PBT, proton beam therapy.
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is because the number of patients who could receive PBT 
was limited in the earlier period of the study, and most 
patients in the study received PBT recently (Fig. 4). The 
number of pediatric patients treated by PBT rapidly increased 
in the 2000s. This change occurred because a central institute 
for PBT in pediatrics was established in 2002 and a second 
institute later started for performance of clinical trials of 
PBT in pediatrics, which has relieved the financial burden 
on families. Follow up was also difficult for some patients 
who had to travel long distances due to education or a 
job. Some patients also do not like to come to the hospital 
after cure. In addition, photon radiotherapy is covered by 
insurance, but PBT is expensive in Japan. Also, many severe 
cases that could not be treated using other therapy were 
included in this study, and many of these patients could 
not continue long- term follow up because of tumor pro-
gression, as indicated by the estimated 3- , 5- , 10- year survival 
rates of 67.4%, 61.4%, and 58.7%, respectively.
The relatively short follow- up period prevents a firm 
conclusion on late toxicities. However, our results suggest 
that PBT may be possible for patients who cannot receive 
photon radiotherapy, of whom there were 41 in the cur-
rent study (12%). Treatment outcomes were poor for 
these patients compared to those for whom photon radio-
therapy was possible, and some patients experienced severe 
toxicities, but at least they had an opportunity for treat-
ment. Recent irradiation history also affected the prognosis, 
with patients with severe risks or recurrent disease having 
a poorer prognosis, even with PBT. However, patients 
who could receive photon radiotherapy but had a risk 
of toxicity due to an overdose were able to undergo PBT 
safely. IQ after irradiation may be affected by age at irra-
diation, dose, irradiation volume, and mean normal brain 
dose [23]. Therefore, PBT may reduce intelligence retar-
dation relative to other radiotherapy. Mizumoto found 
that PBT for pediatric ependymoma could reduce the 
dose to normal brain by 28–64% (median 47%) compared 
to photon radiotherapy [24], and Beltran et al. found 
that PBT could reduce the whole brain dose by 22% and 
the whole body dose by 43% in pediatric patients with 
craniopharyngioma [25]. Macdonald et al. showed that 
normal intelligence was maintained and only a few patients 
developed evidence of growth hormone deficiency, hypo-
thyroidism, or hearing loss after PBT at doses of 54 to 
60 GyE for ependymoma [16]. However, it is difficult to 
demonstrate actual reduction of treatment risk clinically. 
Pediatric solid malignancies occur less frequently than 
adult cancer, and a randomized study may be ethically 
unacceptable because PBT seems to be better in principle. 
In addition, follow- up for a few decades is necessary. 
Further establishment of the efficacy and safety of PBT 
for pediatric patients will require accumulation of more 
cases and longer term follow up.
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